Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
Cancer Treatment Reports|March 1, 1986
Phase II trial of carboplatin in non-small cell lung cancerI N Olver, R C Donehower, D A Van Echo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic studyE K Rowinsky, S D Baker, K Burks, et al.
Investigational New Drugs|November 1, 1989
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I studyE K Rowinsky, L B Grochow, A Hantel, et al.
Leukemia|June 1, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrationsE K Rowinsky, B A Conley, R J Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cardiac disturbances during the administration of taxolE K Rowinsky, W P McGuire, T Guarnieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumorsE C Dees, L R Whitfield, W R Grove, et al.
Investigational New Drugs|August 1, 1990
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancerM J Kennedy, R C Donehower, L B Grochow, et al.
Journal of the National Cancer Institute|December 19, 1990
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitorsE K Rowinsky, R C Donehower, J L Spivak, et al.
Cancer Research|November 1, 1987
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological studyE K Rowinsky, D S Ettinger, W P McGuire, et al.
Cancer Treatment Reports|November 1, 1985
Tastes associated with parenteral chemotherapy for breast cancerJ H Fetting, P M Wilcox, V R Sheidler, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
Cancer Treatment Reports|March 1, 1986
Phase II trial of carboplatin in non-small cell lung cancerI N Olver, R C Donehower, D A Van Echo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic studyE K Rowinsky, S D Baker, K Burks, et al.
Investigational New Drugs|November 1, 1989
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I studyE K Rowinsky, L B Grochow, A Hantel, et al.
Leukemia|June 1, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrationsE K Rowinsky, B A Conley, R J Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cardiac disturbances during the administration of taxolE K Rowinsky, W P McGuire, T Guarnieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumorsE C Dees, L R Whitfield, W R Grove, et al.
Investigational New Drugs|August 1, 1990
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancerM J Kennedy, R C Donehower, L B Grochow, et al.
Journal of the National Cancer Institute|December 19, 1990
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitorsE K Rowinsky, R C Donehower, J L Spivak, et al.
Cancer Research|November 1, 1987
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological studyE K Rowinsky, D S Ettinger, W P McGuire, et al.
Cancer Treatment Reports|November 1, 1985
Tastes associated with parenteral chemotherapy for breast cancerJ H Fetting, P M Wilcox, V R Sheidler, et al.
Pageof 13